Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study by Ahmed, HU et al.
Ahmed, HU; Hindley, RG; Dickinson, L; Freeman, A; Kirkham, AP;
Sahu, M; Scott, R; Allen, C; van der Meulen, J; Emberton, M (2012)
Focal therapy for localised unifocal and multifocal prostate cancer: a
prospective development study. In: UNSPECIFIED. DOI: 10.1016/S1470-
2045(12)70121-3
Downloaded from: http://researchonline.lshtm.ac.uk/28100/
DOI: 10.1016/S1470-2045(12)70121-3
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Supplementary appendix
This appendix formed part of the original submission and has been peer reviewed. 
We post it as supplied by the authors. 
Supplement to: Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised 
unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 
2012; published online April 17. DOI:10.1016/S1470-2045(12)70121-3.
Focal Therapy for Localised Unifocal and Multifocal Prostate cancer: a prospective 
development study 
 
Supplementary Table. Baseline characteristics in 41 men undergoing focal high intensity focused ultrasound in 
men with unifocal and multifocal localised prostate cancer: sub-group demographics according to ablation type. 
 
Baseline characteristics Type of ablation 
 Unilateral, one area  
(Figure 1a) 
Bilateral, two areas  
(Figure 1b) 
Midline, one area  
(Figure 1c) 
N 20/41 (49%) 15/41 (37%) 6/41 (15%) 
Age (years) * 63 (58.0 – 68.0) 60 (57.0 – 66.0) 63 (62.8 – 66.8) 
Serum PSA (ng/ml) * 6.6 (5.1 – 9.2) 6.6 (6.0 – 7.4) 6.1 (5.0 – 8.7) 
Gleason (TPM biopsies) 
 3+3 
 3+4 
 4+3 
 
6/20 (30%)  
10/20 (50%) 
4 (20%) 
 
5/15 (33%) 
10/15 (67%) 
0 (0%) 
 
2/6 (33%) 
4/6 (67%) 
0 (0%) 
Clinical Stage 
 T1c 
 T2a 
 
19/20 (95%) 
1/20 (5%) 
 
12/15 (80%) 
3/15 (20%) 
 
6/6 (100%) 
0 (0%) 
NCCN risk category 
 Low 
 Intermediate 
 High 
 
5/20 (25%) 
11/20 (55%) 
4/20 (20%) 
 
5/15 (33%) 
10/15 (67%) 
0 (0%) 
 
1/6 (17%) 
5/6 83%) 
0 (0%) 
* median (interquartile range) 
 
